Drug-resistant superbugs drive blockbuster antibacterials

Antibacterial drugs are being elevated to blockbuster status as a new generation of lethal hospital-based superbugs prove resistant to standard therapies, according to a new report from Datamonitor. Community-based infections have always dominated this sector in the past, according to the new report, but drug-resistant superbugs in hospital settings-like MRSA-are changing that. Pfizer's Zyvox and Wyeth's Zosyn have already benefited from the trend and more therapies will be developed as an aging population helps trigger a continued surge in the superbug threat.

- read the UPI article on the Datamonitor report

Related Articles:
Controversial cow drug nears FDA approval. Report
VA program slashes MRSA infection rates. Report
Study: Disinfectant cuts down on MRSA. Report

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.